Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study (Q37027750)
Jump to navigation
Jump to search
scientific article published on 19 August 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study |
scientific article published on 19 August 2011 |
Statements
1 reference
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study (English)
1 reference
William G Wierda
1 reference
Swaminathan Padmanabhan
1 reference
Geoffrey W Chan
1 reference
Ira V Gupta
1 reference
Steen Lisby
1 reference
Anders Osterborg
1 reference
Hx-CD20-406 Study Investigators
1 reference
1 reference
Identifiers
1 reference